To compare two dugs ,Olanzapine and Haloperidol in psychosis patients.
Phase 3
- Conditions
- Health Condition 1: F259- Schizoaffective disorder, unspecifiedHealth Condition 2: F259- Schizoaffective disorder, unspecifiedHealth Condition 3: F259- Schizoaffective disorder, unspecified
- Registration Number
- CTRI/2018/11/016425
- Lead Sponsor
- VENKATA AKSHEENA VARAHI VEDAM
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
A newly diagnosed schizophrenia acording to DSM-V criteria
Exclusion Criteria
Known allergic to Olanzapine or Haloperidol
-Unstable patients unable to give consent for the study
-Liver failure and kidney failure patients
-Pregnant women and lactating mothers
-Subject who is currently enrolled in another investigational drug study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method